Treatment of severe venous thrombo-embolism with intravenous Hirudin (HBW 023): an open pilot study.
Recombinant Hirudin (rH) is an anticoagulant agent with a specific antithrombin activity independent of antithrombin III. We report the results of the first open pilot study on the curative treatment of acute venous thrombo-embolism (VTE) with rH (HBW 023) in ten patients. The dose of rH tested was 0.07 mg/kg (i.v. bolus) followed by 0.05 mg kg-1 h-1 (i.v. infusion) for 5 days, without activated partial thromboplastin time (APTT) adjustment. Within the trial, no death, VTE recurrence or major bleeding was observed; lung scan pulmonary vascular obstruction improved from 44 to 37%, whereas the venographic Marder score was unchanged; APTT ratio ranged between 1.2 and 2.8. The dose of rH assessed in this study seems to be safe and efficient in the treatment of acute VTE.
Parent
F
F
Department of Pneumology, Hôpital Antoine Béclère, Université Paris-Sud, Clamart, France.
Bridey
F
F
Dreyfus
M
M
Musset
D
D
Grimon
G
G
Duroux
P
P
Meyer
D
D
Simonneau
G
G
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D024764:Hirudin Therapy; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy* / Q000209:etiology; D013924:Thrombophlebitis / Q000150:complications
D011994:Recombinant Proteins